IP Library Granted Patent US 8,242,130
Granted Patent B2
US 8,242,130 · App. 12/369,296 · Granted Aug 14, 2012

Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,242,130
App. No.
12/369,296
Granted
Aug 14, 2012
Kind
B2
Abstract

The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

Claims (106)

1. A compound of Formula I:

wherein

X is O;

Y is CO;

R 1 , R 3 , R 4 , R 5 , R 6 , R 8 , and R 9 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;

R 2 is selected from alkoxy, aryloxy, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;

R 7 is selected from aryloxy, alkyl, alkenyl, alkynyl, amide, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;

R 10 is selected from aryloxy, alkenyl, alkyl, alkynyl, amide, amino, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;

each W is independently selected from C and N, wherein if W is N, then p is 0 and if W is C, then p is 1;

at least one W is N;

Z 1 and Z 3 are each a single bond; and

Z 2 is a double bond;

and pharmaceutically acceptable salts thereof.

2. A compound of Formula VII:

wherein:

R 1 , R 2 , R 3 , R 5 , R 6 , R 3 , R 9 , and R 10 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;

R 7 is selected from aryloxy, alkyl, alkenyl, alkynyl, amide, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or

two adjacent substituents selected from R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are connected in a 5 or 6-membered ring to form a bicyclic aryl or bicyclic heteroaryl;

and pharmaceutically acceptable salts thereof.

3. A compound that is 2-(4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1 , where R 7 is hydroxyl.

5. A compound according to claim 1 , wherein at least one W in the A ring is N.

6. A compound according to claim 1 , wherein R 5 , R 6 , R 8 , R 9 and R 10 are each hydrogen.

7. A compound according to claim 1 , wherein at least one W in the B ring is N.

8. A compound according to claim 1 , wherein the W in the C ring is selected from N and NR 10 , where R 10 is hydrogen or methyl.

9. A compound according to claim 1 , wherein R 8 is halogen.

10. A compound according to claim 1 , wherein at least one of R 1 , R 2 , R 3 and R 4 is alkoxy.

11. A compound selected from

2-(5-Methoxy-pyridin-2-yl)-chromen-4-one;

2-(5-Hydroxy-pyridin-2-yl)-chromen-4-one;

2-(6-Hydroxy-pyridin-3-yl)-chromen-4-one;

5,7-Dimethoxy-2-(4′-hydroxy-phenyl)-quinolin-4-one;

5,7-Dihydroxy-2-(4-hydroxy-phenyl)-quinolin-4-one;

2-(4-Hydroxy-phenyl)-pyrano[3,2-b]pyridin-4-one;

2-(4-Methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one;

2-(4-Hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one;

2-(4-(2-Hydroxyethoxy)phenyl)-4H-pyrano[2,3-b]pyridine-4-one;

2-(3-Fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridine-4-one;

2-(4-Hydroxy-3-methylphenyl)-4H-pyrano[2,3-b]pyridine-4-one;

4-(4-Oxo-4H-pyrano[2,3-b]pyridine-2-yl)benzonitrile;

2-(3-Chloro-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one;

2-(3-Bromo-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one;

2-(4-Hydroxy-3-methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one;

2-(4-Hyd roxy-phenyl)-pyrano[2,3-c]pyridin-4-one;

2-(4-hydroxy-phenyl)-pyrano[3,2-c]pyridin-4-one;

3-(4-Hydroxyphenyl)-2H-isoquinolin-1-one;

3-(3-Fluoro-4-hydroxyphenyl)-5-methoxyisoquinolin-1(2H)-one;

2-Fluoro-4-(5-methoxy-1-(methylamino)-isoquinolin-3-yl)phenol;

6-Naphthalen-2-yl-pyridin-3-ol;

4-Isoquinolin-3-yl-phenol;

4-(1,6-Naphthyridin-7-yl)phenol;

2-(4-Hydroxy-phenyl)-[1,4]naphthoquinone;

2-(4-Hydroxyphenyl)benzo[e][1,3]oxazin-4-one;

6-Naphthalen-2-yl-pyridin-3-ol;

2-(4-Ethoxycarbonyloxy-phenyl)-4-oxo-4H-quinoline-1-carboxylic acid ethyl ester;

4-(4-oxo-4H-pyrano[2,3-b]pyridine-2-yl)phenyl acetate;

4-(Isoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate;

4-(1-Oxo-1,2-dihydroisoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate;

5,7-Difluoro-2-(4-hydroxy-phenyl)-chromen-4-one;

2-(3,5-Difluoro-4-hydroxyphenyl)chromen-4-one;

2-(4-Hydroxy-3,5-dimethylphenyl)chromen-4-one;

2-(4-Methoxy-phenyl)-thiochromen-4-one;

2-(4-Hydroxy-phenyl)-thiochromen-4-one;

2-(4-Hydroxyphenyl)-3-methyl-4H-chromen-4-one;

4-(6-Bromo-4-oxo-4H-chromen-2-yl)-2-fluorophenyl acetate;

1-(2-Nitro-4-methoxy-phenyl)-chromen-4-one;

2-(4-Hydroxy-2-nitrophenyl)chromen-4-one;

2-(2-Amino-4-methoxy-phenyl)-chromen-4-one;

2-(2-Amino-4-hydroxy-phenyl)-chromen-4-one;

N-[5-Hydroxy-2-(4-oxo-4H-chromen-2-yl)-phenyl]acetamide;

6-Hydroxy-2-(4-hydroxymethylphenyl)chromen-4-one;

2-(2-Fluoro-4-hydroxyphenyl)chromen-4-one;

2-(4-Hydroxyphenyl)-8-nitro-4H-chromen-4-one;

2-(4-Hydroxyphenyl)-8-methoxy-4H-chromen-4-one;

2-(4-Hydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one;

2-(3-Bromo-4-hydroxyphenyl)-4H-chromen-4-one;

2-(4-Hydroxyphenyl)-4-oxo-4H-chromene-6-carbonitrile;

2-(4-Methoxy-phenyl)-chromen-4-one;

2-(3-Fluoro-4-hydroxyphenyl)chromen-4-one;

2-(4-Hydroxyphenyl)-4-oxo-4H-chromene-6-sulfonic acid;

6-Hydroxymethyl-2-(4-hydroxyphenyl)chromen-4-one;

6-((Dimethylamino)methyl)-2-(4-hydroxyphenyl)-4H-chromen-4-one;

8-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;

2-(4-Hydroxy-phenyl)-chromen-4-one;

7-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;

5-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;

5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;

5,7-Dihydroxy-2-phenyl-chromen-4-one;

5-Hydroxy-2-phenyl-chromen-4-one;

2-(4-Acetoxy-phenyl)-thiochromen-4-one;

2-(4-Acetoxy-phenyl)-1,1-dioxo-1H-1λ 6 -thiochromen-4-one;

2-(4-Hydroxy-phenyl)-1,1-dioxo-1H-1λ 6 -thiochromen-4-one;

2-(2-(4-Hydroxyphenyl)-4-oxo-4H-chromen-3-yl)acetonitrile;

3-(Hydroxymethyl)-2-(4-hydroxyphenyl)-4H-chromen-4-one;

2-(4-Hydroxyphenyl)-3-(methoxymethyl)-4H-chromen-4-one;

4-Naphthalen-2-yl-phenol;

3-(4-Hydroxyphenyl)-naphthalene-1-ol;

4-(Benzo[b][1,4]dioxin-2-yl)phenyl acetate;

4-(Benzo[b][1,4]dioxin-2-yl)phenol;

4-(4H-Chromen-2-yl)-phenol;

Nicotinic acid 4-(4-oxo-4H-chromen-2-yl)-phenyl ester;

Acetic acid 4-(4-oxo-4H-chromen-2-yl)-phenyl ester;

2-Amino-5-guanidino-pentanoic acid 4-(4-oxo-4H-chromen-2-yl)phenyl ester; and

2-(4-(Nicotinoyloxy)phenyl)-4-oxo-4H-chromene-5,7-diyl dinicotinate,

and pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition comprising a compound according to claim 1 , 2 , or 11 , and a pharmaceutically acceptable carrier.

Assignments (12)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 058655 FRAME 0643. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Jan 27, 2022
From: RESVERLOGIX CORP.
To: HEPALINK (HONG KONG) LIMITED
Reel/Frame 058887/0288 →
SECURITY INTEREST Recorded Jan 14, 2022
From: RESVERLOGIX CORP.
To: HEPALINK (HONG KONG) LIMITED
Reel/Frame 058655/0643 →
RELEASE OF SECURITY INTEREST Recorded Jan 12, 2021
From: VISION LEADER LIMITED
To: RESVERLOGIX CORP.
Reel/Frame 054888/0506 →
RELEASE OF SECURITY INTEREST Recorded Oct 17, 2019
From: THIRD EYE CAPITAL CORPORATION
To: RESVERLOGIX CORP.
Reel/Frame 050763/0175 →
SECURITY INTEREST Recorded Sep 27, 2019
From: RESVERLOGIX CORP.
To: VISION LEADER LIMITED
Reel/Frame 050518/0714 →
SECURITY INTEREST Recorded Jun 14, 2018
From: RESVERLOGIX CORP.
To: THIRD EYE CAPITAL CORPORATION
Reel/Frame 046090/0103 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2017
From: CAMBRIDGE BAY FINANCE LTD.
To: RESVERLOGIX CORP.
Reel/Frame 044368/0868 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2017
From: EASTERN CAPITAL LIMITED
To: RESVERLOGIX CORP.
Reel/Frame 044368/0856 →
SECURITY INTEREST Recorded Sep 14, 2017
From: RESVERLOGIX CORP.
To: CAMBRIDGE BAY FINANCE LTD.
Reel/Frame 043592/0343 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 7, 2014
From: RESVERLOGIX CORP.
To: EASTERN CAPITAL LIMITED
Reel/Frame 033279/0137 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 11/255,103 FILED 10/20/2005 WITH ATTORNEY DOCKET NO. 09741.0008-00000 PREVIOUSLY RECORDED ON REEL 028065 FRAME 0955. ASSIGNOR(S) HEREBY CONFIRMS THE APPLICATION NO. 12/369,296 FILED FEBRUARY 11, 2009 WITH ATTORNEY DOCKET NO. 09741.0008-01000. Recorded Apr 19, 2012
From: WONG, NORMAN C. W., DR.; TUCKER, JOSEPH E. L., DR.; HANSEN, HENRIK C., DR.; CHIACCHIA, FABRIZIO S.; MCCAFFREY, DAVID
To: RESVERLOGIX CORP.
Reel/Frame 028078/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2012
From: WONG, NORMAN C. W., DR.; TUCKER, JOSEPH E. L., DR.; HANSEN, HENRIK C., DR.; CHIACCHIA, FABRIZIO S.; MCCAFFREY, DAVID
To: RESVERLOGIX CORP.
Reel/Frame 028065/0955 →